12 research outputs found
Recommended from our members
Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain
Background:
Protein tyrosine kinases are important regulators of cellular homeostasis with tightly
controlled catalytic activity. Mutations in kinase-encoding genes can relieve the autoinhibitory
constraints on kinase activity, can promote malignant transformation, and appear to be a major
determinant of response to kinase inhibitor therapy. Missense mutations in the EGFR kinase
domain, for example, have recently been identified in patients who showed clinical responses
to EGFR kinase inhibitor therapy.
Methods and Findings:
Encouraged by the promising clinical activity of epidermal growth factor receptor (EGFR)
kinase inhibitors in treating glioblastoma in humans, we have sequenced the complete EGFR
coding sequence in glioma tumor samples and cell lines. We identified novel missense
mutations in the extracellular domain of EGFR in 13.6% (18/132) of glioblastomas and 12.5% (1/
8) of glioblastoma cell lines. These EGFR mutations were associated with increased EGFR gene
dosage and conferred anchorage-independent growth and tumorigenicity to NIH-3T3 cells.
Cells transformed by expression of these EGFR mutants were sensitive to small-molecule EGFR
kinase inhibitors.
Conclusions:
Our results suggest extracellular missense mutations as a novel mechanism for oncogenic
EGFR activation and may help identify patients who can benefit from EGFR kinase inhibitors for
treatment of glioblastoma
Bid Regulates the Pathogenesis of Neurotropic Reovirus
Reovirus infection leads to apoptosis in both cultured cells and the murine central nervous system (CNS). NF-κB-driven transcription of proapoptotic cellular genes is required for the effector phase of the apoptotic response. Although both extrinsic death-receptor signaling pathways and intrinsic pathways involving mitochondrial injury are implicated in reovirus-induced apoptosis, mechanisms by which either of these pathways are activated and their relationship to NF-κB signaling following reovirus infection are unknown. The proapoptotic Bcl-2 family member, Bid, is activated by proteolytic cleavage following reovirus infection. To understand how reovirus integrates host signaling circuits to induce apoptosis, we examined proapoptotic signaling following infection of Bid-deficient cells. Although reovirus growth was not affected by the absence of Bid, cells lacking Bid failed to undergo apoptosis. Furthermore, we found that NF-κB activation is required for Bid cleavage and subsequent proapoptotic signaling. To examine the functional significance of Bid-dependent apoptosis in reovirus disease, we monitored fatal encephalitis caused by reovirus in the presence and absence of Bid. Survival of Bid-deficient mice was significantly enhanced in comparison to wild-type mice following either peroral or intracranial inoculation of reovirus. Decreased reovirus virulence in Bid-null mice was accompanied by a reduction in viral yield. These findings define a role for NF-κB-dependent cleavage of Bid in the cell death program initiated by viral infection and link Bid to viral virulence
Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain
BACKGROUND: Protein tyrosine kinases are important regulators of cellular homeostasis with tightly controlled catalytic activity. Mutations in kinase-encoding genes can relieve the autoinhibitory constraints on kinase activity, can promote malignant transformation, and appear to be a major determinant of response to kinase inhibitor therapy. Missense mutations in the EGFR kinase domain, for example, have recently been identified in patients who showed clinical responses to EGFR kinase inhibitor therapy. METHODS AND FINDINGS: Encouraged by the promising clinical activity of epidermal growth factor receptor (EGFR) kinase inhibitors in treating glioblastoma in humans, we have sequenced the complete EGFR coding sequence in glioma tumor samples and cell lines. We identified novel missense mutations in the extracellular domain of EGFR in 13.6% (18/132) of glioblastomas and 12.5% (1/8) of glioblastoma cell lines. These EGFR mutations were associated with increased EGFR gene dosage and conferred anchorage-independent growth and tumorigenicity to NIH-3T3 cells. Cells transformed by expression of these EGFR mutants were sensitive to small-molecule EGFR kinase inhibitors. CONCLUSIONS: Our results suggest extracellular missense mutations as a novel mechanism for oncogenic EGFR activation and may help identify patients who can benefit from EGFR kinase inhibitors for treatment of glioblastoma
Effect of Delayed Inferior Vena Cava Filter Retrieval After Early Initiation of Anticoagulation
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
EGFR Missense Mutations Are Transforming and Tumorigenic
<div><p>(A) Anchorage-independent growth of NIH-3T3 cells expressing various <i>EGFR</i> alleles as mean number of colonies ± standard deviation (bar graph, above). The lanes (below) show EGFR and actin immunoblots of whole cell lysates from NIH-3T3 subclones plated in soft agar. EGF (10 ng/ml) was added to the top agar where indicated.</p>
<p>(B) Tumorigenicity of NIH-3T3 cells stably expressing the indicated <i>EGFR</i> alleles in nude mice. Mean tumor size ± standard deviation was determined 3–4 wk after subcutaneous inoculation into nude mice (<i>n</i> = 6 per cell line).</p></div
EGFR Missense Mutations in Glioblastoma Cluster in the Extracellular Domain and Are Associated with Increased <i>EGFR</i> Gene Dose
<div><p>(A) Location of missense mutations within the EGFR protein in a panel of 151 gliomas (132 glioblastomas, 11 WHO grade III gliomas, and eight glioblastoma cell lines). Each diamond represents one sample harboring the indicated mutation. Amino acid (AA) numbers are based on the new convention for EGFR numbering, which starts at the initiator methionine of pro-EGFR. Ligand-binding domains (I and III), cysteine-rich domains (II and IV), kinase domain (kinase), and the extracellular deletion mutant EGFRvIII [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030485#pmed-0030485-b045" target="_blank">45</a>] are indicated as reference.</p>
<p>(B) Increased <i>EGFR</i> gene dose in tumors harboring <i>EGFR</i> missense mutations. The array (left) shows a high-resolution view of Affymetrix 100K SNP array at the <i>EGFR</i> gene locus for ten glioblastoma tumors and three normal controls (sample numbers are indicated above each column). <i>EGFR</i> mutation and log<sub>2</sub> ratio (see <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030485#st2" target="_blank">Methods</a>) are indicated below each column. The plot (left) shows a comparison of <i>EGFR</i> gene copy number determination by SNP array (y-axis, EGFR log<sub>2</sub> ratios) and FISH (x-axis). AMP, amplified; NON-AMP, non amplified.</p>
<p>(C) RT-PCR for <i>EGFRvIII</i> and full-length <i>EGFR</i> in 14 fresh-frozen glioblastoma tumors (see <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030485#st2" target="_blank">Methods</a>). The upper band represents full-length <i>EGFR</i> (1,044 bp), the lower band <i>EGFRvIII</i> (243 bp), and the inset shows glyceraldehyde-3-phosphate dehydrogenase <i>(GAPDH)</i> RT-PCR results.</p></div